Survivin-specific T-cell reactivity correlates with tumor response and patient survival: A phase-II peptide vaccination trial in metastatic melanoma

Becker JC, Andersen MH, Hofmeister-Mueller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kämpgen E, Opitz A, Zapatka M, Broecker EB, Straten PT, Schrama D, Ugurel S (2012)

Publication Status: Published

Publication Type: Journal article, Original article

Publication year: 2012

Journal

Cancer Immunology, Immunotherapy Springer Verlag (Germany)

Book Volume: 61

Pages Range: 2091-2103

Journal Issue: 11

DOI: 10.1007/s00262-012-1266-9

Involved external institutions

Herlev Hospital DK Denmark (DK) Julius-Maximilians-Universität Würzburg DE Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) DE Germany (DE)

How to cite

APA:

Becker, J.C., Andersen, M.H., Hofmeister-Mueller, V., Wobser, M., Frey, L., Sandig, C.,... Ugurel, S. (2012). Survivin-specific T-cell reactivity correlates with tumor response and patient survival: A phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunology, Immunotherapy, 61(11), 2091-2103. https://doi.org/10.1007/s00262-012-1266-9

MLA:

Becker, Juergen C., et al. "Survivin-specific T-cell reactivity correlates with tumor response and patient survival: A phase-II peptide vaccination trial in metastatic melanoma." Cancer Immunology, Immunotherapy 61.11 (2012): 2091-2103.

BibTeX: Download